Propeller Health-MIR, Senseonics-Roche, and more digital health deals

By Heather Mack

Madison, Wisconsin-based Propeller Health, which offers a digitally-guided respiratory therapy platform, has teamed up with Medical International Research (MIR) to offer several of the Italian health technology company’s mobile and clinical spirometers alongside the Propeller system. The addition of sprirometers will give Propeller a more complete vision of the people using their platform, which works to improve management of respiratory conditions like asthma and COPD and also includes eight FDA-cleared sensors for connected inhalers. Healthcare organizations and pharmaceutical partners using Propeller can incorporate the MIR spirometers into their existing clinical programs, and data from the devices will automatically be routed to the Propeller platform where people and their doctors can assess their lung function and treatment status. More

Germantown, Maryland-based Senseonics, which is working on a long-term implantable continuous glucose monitor called Eversense, has expanded its exclusive distribution agreement with Roche. Now, Roche will have exclusive rights to promote, market and sell the Eversense product line to diabetes clinics and patients in in most of Europe (excluding Scandinavia and Finland), the Middle East (except Israel) and Africa. This builds on the two companies’ previous agreement in May that awarded Roche the same privileges in Germany, Italy and the Netherlands.  More

Medical device company Medtronic has partnered with wearable maker Fitbit to integrate data from a continuous glucose monitor and physical activity data in streamlined application. With the iPro2 myLog mobile app, people who use Medtronic’s iPro2 CGM system and also use a Fitbit device can easily combine data generated from both, which provides them with meaningful insights into how exercise impacts glucose levels as well as more efficient management of their diabetes care. Additionally, users can share the information with their healthcare team. More

Marlborough, Massachusetts-based pharma company Sunovion will use the Empatica Embrace, a wearable device for seizure detection, in a phase 4 clinical study of Aptiom, a drug meant to reduce seizures in people with epilepsy. The Empatica Embrace is the latest version of a wearable developed by Rosalind Picard, an MIT professor who formerly co-founded a company called Affectiva.“We believe that incorporating digital health technologies into traditional treatment paradigms has the potential to inform and enhance best practices and further empower people living with serious medical conditions and their families,” Dr. Antony Loebel, executive vice president and chief medical officer at Sunovion, said in a statement. “We look forward to sharing the results of this study and continue to look for opportunities for Sunovion to leverage advances in digital health.” More

Phoenix, Arizona-based , which offers a marketplace for chronic disease management programs, has partnered with mobile diabetes prevention program . Yes Health’s offering, which is recognized by the Centers for Disease Control and is a covered diabetes prevention program, connects people who are at risk of developing type 2 diabetes with one-on-one coaching, nutrition and fitness tracking, as well as personalized health advice. The app offers in-the-moment coaching from a nutritionist, fitness trainer or wellbeing expert, and users can get real-time nutrition and meal feedback by taking a picture on their smartphone and getting tips in response. The app also connects to a digital scale, and users will have the option to add a Fitbit (at no cost) to the program in January 2017. More

Acheter Vardénafil